December 6, 2017: Here are four stocks trading with heavy volume among 121 equities making new 52-week lows in Wednesday’s session. On the NYSE decliners led advancers by about 3 to 2 and on the Nasdaq, decliners led advancers by more than 9 to 5.
The recent €25.4m ($27.7m) private placement provides Erytech with a healthy cash balance, which should allow effective execution on the strategy to advance and accelerate Graspa/Eryasp in the US, to move development into front-line ALL (acute lymphoblastic leukemia) and to continue pursuing new indications. Two-year follow-up ALL data for Graspa were recently presented at ASH, reinforcing its potential as an effective, safe therapy for patients with few options in this indication. Our valuation is increased to $354.2m with the higher cash balance.